



@ausbiotech
#ausmedtech2023

AusMedtech

Australia's Medtech
Conference

2023

BACK TO THE FUTURE
24-25 MAY | ADELAIDE

HOST INDUSTRY BODY



HOST STATE PARTNERS



Government
of South Australia



Business
Events
Adelaide

BIOINVISIBLE™

The future in medical devices

a simple,
high-performance,
drug-free polymer coating

Device failure is a persistent and serious problem

Medical device failures can be life-threatening and pose a significant burden on the healthcare budget

Thrombosis and Restenosis

- ❖ Stents
- ❖ Vascular Grafts
- ❖ Heart Valves



Device failure is a persistent and serious problem

Medical device failures can be life-threatening and pose a significant burden on the healthcare budget

Biofilm and Infection

- ❖ Catheters
- ❖ Orthopaedic implants



Device failure is a persistent and serious problem

Medical device failures can be life-threatening and pose a significant burden on the healthcare budget

Fibrosis & inflammation

- ❖ Breast implants
- ❖ Surgical mesh
(hernia & pelvic prolapse)




Introducing BIOINVISIBLE™ – a new drug-free medical coating

BIOINVISIBLE is:

- ❖ Anti-thrombogenic
- ❖ Anti-biofilm
- ❖ Anti-fibrotic

Reduces need for costly re-intervention



How BIOINVISIBLE works

A Hyperbranched Polyglycerol (HPG) – very HYDROPHILIC


Biocompatible and safe – NAMSA tested

Patents granted – US, EU, CN, JP, AU





Cells & Platelets

Proteins


Microorganisms



The BIOINVISIBLE process



Non-depositing plasma
Time: 2 - 20 min



Monomer (solvent-free)
Time: 2 - 24 hr

Proof that BIOINVISIBLE works


Uncoated surface



Anti-thrombogenic



Anti-biofilm



Anti-fibrotic


BIOINVISIBLE surface



Chandler loop thrombosis model



P. aeruginosa, *S. aureus*,
C. albicans, *A. baumannii*, *E. coli*



Implant mouse model

Large commercial opportunity



Aiming to raise up to \$2 million

Pre-money value of \$4.8 million

- Expecting launch of first BIOINVISIBLE product in 3-4 years
- Anticipating revenues of >\$10M per coated product

B2B Enterprise



Development Plan - 12-18 months:

STENTS:

- ✓ Extensive data set
- ✓ Up-scaled to meet clinical needs
- ✓ Interest from several companies

CATHETERS & ORTHOPAEDIC IMPLANTS:

- ✓ Generate data set
- ✓ Demonstrate robustness
- ✓ Optimise process for range of devices
- ✓ Scale up for commercial demand
- ✓ Secure interest from companies

Outcome - long-term product development agreement and/or commercial deal

Opportunity summary:

BIOINVISIBLE - helping to create safer and better outcomes for patients.

- ❖ Addresses significant unmet need
- ❖ Drug-free device coating
- ❖ IP protected
- ❖ Targets several device applications
- ❖ Commercial ready
- ❖ Can save healthcare industry \$\$ billions

About TekCyte

Post-revenue company delivering market-leading medical coatings

- Wound care coating licensed and in Ph1 Clinical trial
- Quality manufacturing capability
- Expanding into multiple markets